Genetic Determinants of Response to P2Y₁₂ Inhibitors and Clinical Implications

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Drug Metabolism

Background:

• Clopidogrel is a prodrug requiring activation by the CYP2C19 enzyme.
• Loss-of-function (LoF) polymorphisms in CYP2C19 reduce the formation of active clopidogrel metabolite.
• Reduced clopidogrel effectiveness is observed in patients with LoF alleles after acute coronary syndrome or percutaneous coronary intervention.

Purpose of the Study:

• To highlight the impact of CYP2C19 genotype on clopidogrel efficacy.
• To discuss alternative P2Y12 inhibitors unaffected by CYP2C19 genotype.
• To emphasize the clinical implications of CYP2C19-guided antiplatelet therapy selection.

Main Methods:

• Review of existing literature on CYP2C19 genetics and antiplatelet drug response.
• Analysis of clinical outcomes data in patients with varying CYP2C19 genotypes.
• Comparison of clopidogrel, prasugrel, and ticagrelor efficacy based on CYP2C19 status.

Main Results:

• Approximately 30% of the population carries CYP2C19 LoF alleles, leading to diminished clopidogrel effectiveness.
• Prasugrel and ticagrelor offer improved outcomes in patients with LoF alleles as their metabolism is CYP2C19-independent.
• CYP2C19-guided selection of P2Y12 inhibitors demonstrates potential for improved patient outcomes.

Conclusions:

• CYP2C19 genotype significantly influences clopidogrel efficacy, particularly in cardiovascular patients.
• Alternative P2Y12 inhibitors (prasugrel, ticagrelor) are recommended for individuals with CYP2C19 LoF alleles.
• Wider adoption of CYP2C19 genotyping could optimize antiplatelet therapy selection and improve clinical outcomes, despite current clinical practice limitations.